AI English summary of an SEC filing — figures as filed
Moderna MRNAModerna said it reported Q3 2024 total revenue of $1.9 billion, GAAP net income of $13 million and GAAP earnings per share of $0.03. For Q3 2023, it reported a net loss of $(3.6) billion and a loss per share of $(9.53).
Key points
AI summaryModerna said it reported Q3 2024 total revenue of $1.9 billion, GAAP net income of $13 million and GAAP earnings per share of $0.03. For Q3 2023, it reported a net loss of $(3.6) billion and a loss per share of $(9.53).
The company reported Spikevax sales of $1.8 billion for Q3, including $1.2 billion in U.S. sales and $0.6 billion in international sales, and mRESVIA sales of $10 million. It cited the timing of the mRESVIA approval and recommendation, which came late in the contracting season after many customers had completed their orders, as the reason mRESVIA sales were lower than expected.
Moderna said cost of sales for Q3 was $514 million, down 77% from a year earlier. It said cost of sales as a percentage of net product sales was 28% for Q3 2023, versus 128%. The company also said selling, general and administrative expenses fell 36% from a year earlier to $281 million.
The company said cash, cash equivalents and investments were $9.2 billion as of September 30, 2024, compared with $10.8 billion as of June 30, 2024. It reiterated its full-year net product sales outlook of $3.0 to $3.5 billion and put its full-year research and development expense outlook at $4.6 to $4.7 billion, versus the prior $4.8 billion.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Moderna Revenue $1.9 billion, Net Income $13 million in Q3 2024
Moderna said it reported Q3 2024 total revenue of $1.9 billion, GAAP net income of $13 million and GAAP earnings per share of $0.03. For Q3 2023, it reported a net loss of $(3.6) billion and a loss per share of $(9.53).
Source · Based on the filing body and exhibits
Spikevax Sales $1.8 billion, mRESVIA Sales $10 million
The company reported Spikevax sales of $1.8 billion for Q3, including $1.2 billion in U.S. sales and $0.6 billion in international sales, and mRESVIA sales of $10 million. It cited the timing of the mRESVIA approval and recommendation, which came late in the contracting season after many customers had completed their orders, as the reason mRESVIA sales were lower than expected.
Source · Based on the filing body and exhibits
Cost of Sales $514 million, SG&A $281 million
Moderna said cost of sales for Q3 was $514 million, down 77% from a year earlier. It said cost of sales as a percentage of net product sales was 28% for Q3 2023, versus 128%. The company also said selling, general and administrative expenses fell 36% from a year earlier to $281 million.
Source · Based on the filing body and exhibits
Cash $9.2 billion, 2024 Full-Year Outlook
The company said cash, cash equivalents and investments were $9.2 billion as of September 30, 2024, compared with $10.8 billion as of June 30, 2024. It reiterated its full-year net product sales outlook of $3.0 to $3.5 billion and put its full-year research and development expense outlook at $4.6 to $4.7 billion, versus the prior $4.8 billion.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…